EA201791275A1 - Способы получения ctp-модифицированных полипептидов длительного действия - Google Patents

Способы получения ctp-модифицированных полипептидов длительного действия

Info

Publication number
EA201791275A1
EA201791275A1 EA201791275A EA201791275A EA201791275A1 EA 201791275 A1 EA201791275 A1 EA 201791275A1 EA 201791275 A EA201791275 A EA 201791275A EA 201791275 A EA201791275 A EA 201791275A EA 201791275 A1 EA201791275 A1 EA 201791275A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ctp
obtaining
term
methods
long
Prior art date
Application number
EA201791275A
Other languages
English (en)
Inventor
Орен Гершковиц
Лаура Мошкович
Original Assignee
Опко Байолоджикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Опко Байолоджикс Лтд. filed Critical Опко Байолоджикс Лтд.
Publication of EA201791275A1 publication Critical patent/EA201791275A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0633—Workflow analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0637—Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0639—Performance analysis of employees; Performance analysis of enterprise or organisation operations
    • G06Q10/06393—Score-carding, benchmarking or key performance indicator [KPI] analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0201—Market modelling; Market analysis; Collecting market data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Abstract

В данном документе раскрыт способ изготовления представляющего интерес рекомбинантного полипептида, модифицированного удлиняющим сегментом СТР, в системе культивирования клеток млекопитающих.
EA201791275A 2014-12-10 2015-12-10 Способы получения ctp-модифицированных полипептидов длительного действия EA201791275A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462090124P 2014-12-10 2014-12-10
US201462090104P 2014-12-10 2014-12-10
US201462090116P 2014-12-10 2014-12-10
PCT/IL2015/051197 WO2016092550A2 (en) 2014-12-10 2015-12-10 Methods of producing long acting ctp-modified polypeptides

Publications (1)

Publication Number Publication Date
EA201791275A1 true EA201791275A1 (ru) 2017-12-29

Family

ID=56106835

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791275A EA201791275A1 (ru) 2014-12-10 2015-12-10 Способы получения ctp-модифицированных полипептидов длительного действия

Country Status (22)

Country Link
US (3) US20180111974A1 (ru)
EP (4) EP3230309B1 (ru)
KR (3) KR20200118505A (ru)
CN (1) CN107438623B (ru)
AU (2) AU2015358890B2 (ru)
CO (1) CO2017006870A2 (ru)
EA (1) EA201791275A1 (ru)
ES (1) ES2943359T3 (ru)
HK (2) HK1243444A1 (ru)
HR (1) HRP20230405T8 (ru)
IL (2) IL252778B (ru)
MX (2) MX2017007635A (ru)
NZ (1) NZ733113A (ru)
PE (1) PE20171380A1 (ru)
PH (1) PH12017501089A1 (ru)
PL (1) PL3230309T3 (ru)
RU (2) RU2743295C2 (ru)
SG (1) SG11201704706RA (ru)
SI (1) SI3230309T1 (ru)
TW (2) TW202231657A (ru)
WO (2) WO2016092549A1 (ru)
ZA (1) ZA201704595B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
MX2017007635A (es) 2014-12-10 2017-09-11 Opko Biologics Ltd Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada.
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
HUE064463T2 (hu) * 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
RU2652884C1 (ru) * 2016-11-25 2018-05-03 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Штамм клеток яичников китайского хомячка сно-еро 4а9 - продуцент высокосиалированного эритропоэтина
US20200262887A1 (en) * 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
WO2021005604A1 (en) * 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
WO2022197961A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Methods of administering long-acting growth hormone polypeptides
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
ATE110571T1 (de) 1988-05-06 1994-09-15 Toray Industries Stabile interferon-beta-zusammensetzung.
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
ATE109507T1 (de) * 1989-04-28 1994-08-15 Miles Inc Grossfermenter-inokulation mit gefrorenen zellen.
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU687053B2 (en) * 1993-04-20 1998-02-19 Washington University Modified protein and peptide pharmaceuticals
ES2139081T3 (es) * 1994-06-17 2000-02-01 Applied Res Systems Ars Holding N V Composiciones farmaceuticas que contienen la hormona humana del crecimiento.
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
CN1847265A (zh) * 2005-04-15 2006-10-18 上海市计划生育科学研究所 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途
WO2007092252A2 (en) 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) * 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
AU2011316730B2 (en) * 2010-10-11 2015-12-10 Abbvie Bahamas Ltd. Processes for purification of proteins
JP6242819B2 (ja) 2012-02-14 2017-12-06 オプコ バイオロジクス リミテッド 長時間作用型凝固因子およびその生成方法
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
AU2013250711A1 (en) * 2012-04-19 2014-11-27 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
SG10201610223PA (en) * 2012-11-20 2017-02-27 Opko Biolog Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP2981282B1 (en) * 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
MX2017007635A (es) 2014-12-10 2017-09-11 Opko Biologics Ltd Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada.
EP3310347B1 (en) * 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same

Also Published As

Publication number Publication date
AU2019203609B2 (en) 2021-02-25
US20180111974A1 (en) 2018-04-26
CN107438623A (zh) 2017-12-05
EP4212546A1 (en) 2023-07-19
PE20171380A1 (es) 2017-09-15
AU2019203609A1 (en) 2019-06-13
MX2017007634A (es) 2017-08-28
US20210371487A1 (en) 2021-12-02
SG11201704706RA (en) 2017-07-28
IL252778B (en) 2021-09-30
EP3230309A1 (en) 2017-10-18
KR102527180B1 (ko) 2023-04-27
PH12017501089A1 (en) 2017-10-18
EP4253407A3 (en) 2023-12-06
AU2015358890A1 (en) 2017-07-20
WO2016092550A2 (en) 2016-06-16
IL252788B (en) 2021-09-30
CO2017006870A2 (es) 2018-01-05
TW202231657A (zh) 2022-08-16
EP3230309B1 (en) 2023-03-29
RU2017123789A3 (ru) 2019-01-10
PL3230309T3 (pl) 2023-08-28
EP3240564A4 (en) 2018-05-30
AU2015358890B2 (en) 2019-06-13
HK1243444A1 (zh) 2018-07-13
EP3240564A2 (en) 2017-11-08
HRP20230405T8 (hr) 2023-09-29
RU2021103436A (ru) 2021-02-25
US20160168588A1 (en) 2016-06-16
KR102164352B1 (ko) 2020-10-13
RU2017123789A (ru) 2019-01-10
ZA201704595B (en) 2019-06-26
TWI746427B (zh) 2021-11-21
WO2016092549A1 (en) 2016-06-16
WO2016092550A3 (en) 2016-08-04
KR20220058564A (ko) 2022-05-09
KR20170086664A (ko) 2017-07-26
CN107438623B (zh) 2023-07-14
IL252788A0 (en) 2017-08-31
BR112017012498A2 (pt) 2018-07-31
MX2017007635A (es) 2017-09-11
EP4253407A2 (en) 2023-10-04
NZ733113A (en) 2020-09-25
KR20200118505A (ko) 2020-10-15
IL252778A0 (en) 2017-08-31
TW201638105A (zh) 2016-11-01
SI3230309T1 (sl) 2023-08-31
HRP20230405T1 (hr) 2023-09-01
ES2943359T3 (es) 2023-06-12
HK1246322A1 (zh) 2018-09-07
RU2743295C2 (ru) 2021-02-16

Similar Documents

Publication Publication Date Title
EA201791275A1 (ru) Способы получения ctp-модифицированных полипептидов длительного действия
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
MX2018016258A (es) Metodo de diferenciacion mejorada.
MX2021014712A (es) Polipeptidos de transposasa y sus usos.
MX2017006127A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
IL249828A0 (en) Limbal stem cells of cultured mammals, methods of their creation and uses thereof
BR112016018105A2 (pt) célula eletroquímica, método de produção de uma célula eletroquímica
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
TR201909037T4 (tr) Yeni protein deamidaz.
EP3633029A4 (en) PROCESS FOR CULTURING NATURAL KILLER CELLS USING A TRANSFORMED T LYMPHOCYTE
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
BR112016018562A2 (pt) método de operação de células eletroquímicas compreendendo combustível eletrodepositado.
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
DK3743266T3 (da) 3D-bioprintere med midler til cellekulturovervågning
CL2016001900A1 (es) Sobreexpresión de los reguladores de caminos de n-glicosilación para regular la glicosilación de proteinas recombinante
EP3375863A4 (en) CELL CULTURE METHOD USING A MEDIUM CONTAINING A LAMININ FRAGMENT
BR112019000209A2 (pt) métodos de produção de um produto de fermentação em trichoderma
BR112016021739A2 (pt) Método para preparar um poloxâmero para uso em um meio de cultura de célula
BR112017009152A2 (pt) métodos de produção de proteínas de duas cadeias em bactérias
EP3315601A4 (en) METHOD FOR CULTURING ANIMAL CELL COMPOSITION, METHOD FOR PRODUCING ANIMAL CELL COMPOSITION THEREFOR AND ANIMAL CELL COMPOSITION
EA201791423A1 (ru) Способ получения белка
BR112016006063A2 (pt) método para clarificação de uma colheita de cultura celular em bruto
MY184625A (en) Methods of producing long acting ctp-modified growth hormone polypeptides
EA201690902A1 (ru) Усовершенствованные гранулы, содержащие нативный глютен, и способ их получения